Inflammasome sets sights on Phase III amid eye disease drug’s mid-stage score

Phase 2positiveK8Positive

AI Analysis

Summary

Inflammasome's K8 demonstrated positive Phase 2 results in geographic atrophy by slowing disease progression and trending toward visual acuity improvement, prompting the company to plan Phase 3 development.

Clinical Trial Data

Phase

Outcome Details

K8 slowed disease progression and trended towards improving visual acuity in GA

Importance:6/10

Sentiment:

0.70

Phase 2 dataeye diseasegeographic atrophydisease progressionvisual acuity

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on July 20, 2026 1:05 PM

Read Original